A meta-analysis performed by the Nuffield Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium demonstrated, based on data from the DAPA-CKD and EMPAR-KIDNEY trials, that SGLT2i slows down the progression of CKD in patients with glomerular disease (RR 0.60, 95% CI: 0.46–0.78) and that a solid trend toward benefit can be observed in the case of ischemic/hypertensive kidney disease (RR 0.70; 95% CI: 0.50–1.00). The gene discussed is SLC5A2; the disease is chronic kidney disease.